Biosimilars Market Size By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), By Application (Haematology {Neutropenia, Anaemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukaemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), By Manufacturer (Contract Research and Manufacturing Services, In-house), By Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Published Date: May 2019  |  Report ID: GMI3328

Report Format: PDF   |   Pages: 600   |   Base Year: 2018




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Biosimilars Market size was valued at USD 10.0 billion in 2018 and is expected to witness 27.0% CAGR from 2019 to 2025.
 

U.S. Biosimilars Market, By Product, 2018 & 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Biosimilars market is poised to experience lucrative growth over the forecast period. As per a recent article, biosimilars are estimated to play a significant role in enhancing the public health issue by addressing the customer needs. The potential savings from the use of biosimilars is estimated to be around over USD 100 billion by the year 2020. Increase in demand for biosimilar drugs in order to reduce the healthcare cost will be one of the major market boosting factors.
 

Rising prevalence of chronic diseases across the globe, especially in developing regions owing to rise in sedentary lifestyle and increasing habit of fast food consumption will result in growing number of people suffering from such diseases. Hence, prevalence rate in developed as well as in certain areas in developing nations will augment the demand and adoption rate of biosimilar drugs, fueling the business growth.
 

However, high development cost of the biosimilar drug will be one of the major reasons impeding the adoption rates in under-developed and few developing countries. As per a recent research, it takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. High cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.
 

Biosimilars Market Report Coverage
Report Coverage Details
Base Year: 2018
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Pages: 600 Tables, Charts & Figures: 1245
Geographies covered (34): U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Turkey, Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden, Switzerland, China, Japan, India, South Korea, Australia, New Zealand, Singapore, Malaysia, Rest of The World
Segments covered: Product, Application, Manufacturer, Technology and Region
Companies covered (20): 3SBio, Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences, Dr. Reddy's Laboratories, Elli Lilly and Company, Intas Biopharmaceuticals, Lupin, Merck, Novartis (Sandoz), Ratiopharm, Samsung Bioepis, Sanofi, STADA Arzneimittel, Teva Pharmaceutical, Wockhardt, Zydus Cadila

Request 15% Free Customization on this Report
 

Biosimilars Market, By Product

Germany Biosimilars Market Share, By Product, 2018
Germany Biosimilars Market Share, By Product, 2018

Get more details on this report - Request Free Sample PDF
 

Recombinant non-glycosylated proteins market held the majority market share in the year 2018 and was valued around USD 6,736.2 million. Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor (Filgrastim), insulin and interferon. Recent technological advancements in cell technology and high-throughput analytical techniques will help enable effective production of recombinant non-glycosylated proteins resulting in enhanced sales. Also, recent launch of insulin glargine in major countries and growing demand of filgrastim will further augment the global market growth.
 

Recombinant glycosylated proteins market is estimated to grow at 28.7% over the estimation period. The recombinant glycosylated proteins include erythropoietin, monoclonal antibodies , follitropin and low molecular weight heparin. Increase in number of people suffering from autoimmune diseases, chronic kidney disease and several hematological disorders such as anemia, neutropenia, etc. will lead to growing demand and adoption rate of biosimilar drugs, boosting the industry growth.
 

Biosimilars Market, By Application

Application of biosimilars is highest in hematology segment resulting in major market share. The hematology segment accounted for around USD 4,552.1 million revenue in the year 2018. Advancements in chemotherapy and cancer treatment has helped many patients survive, but many of the patients suffer from side-effects of chemotherapy resulting in chemotherapy-induced anemia. Increase in number of people suffering from blood disorders such as, neutropenia, anemia etc. will boost the sales of biosimilars.
 

Application of biosimilars in oncology segment is estimated to witness rapid growth at 37.2% over the forecast period. The recent approvals of biosimilar for cancer treatment and large number of oncology products in the pipeline will be a major market driving factor. The European Medicines Agency (EMA) approved the first oncology product in the year 2017 and number of other oncology products such as rituximab, trastuzumab and bevacizumab in the year 2018. Hence, recent oncology product approvals will augment the market growth over the estimation period.
 

Biosimilars Market, By Manufacturer

In-house manufacturing of biosimilars held around 75% market share in the year 2018 and was valued at USD 7,843.5 million. In-house manufacturing of the biosimilar products helps the companies to monitor and assess every step on the production and reduces other costs of delivery and shipping. Also, the flexibility and efficiency of the work provided by in-house manufacturing benefits the operational and financial capabilities of the company. Hence, currently in-house manufacturing of biosimilar products will have major market share.
 

Contract research and manufacturing of the biosimilars is forecasted to grow at 28.8% during the projection period. The companies in developing regions of Asia Pacific are forming strategic alliance and partnerships with big global pharma players to manufacture the biosimilars. Currently, there are few companies that give contract manufacturing of biosimilars, but recent strategic developments of the contract manufacturers and low overhead cost of manufacturing will result in growing contract manufacturing of biosimilars.
 

Biosimilars Market, By Technology

Development of biosimilars by recombinant DNA technology (rDNA technology) held over 80% market share and was valued at USD 8,123.6 million in the year 2018. Several biosimilar products such as human growth hormones, insulin, erythropoietin etc. are manufactured using recombinant DNA technology. The technology enhances the capability of the biosimilars to treat the disease immediately and efficiently. Hence, manufacturers use the recombinant DNA technology in order to manufacture biosimilar products.
 

Development of biosimilars by monoclonal antibodies (MAb) technology is forecasted to grow at 30.0% over the estimation period. Increase in number of monoclonal antibody application in treatment of cancer and autoimmune disease has resulted in growing monoclonal antibody technology adoption, fueling the business growth.
 

Biosimilars Market, By Region

Europe Biosimilars Market, By Country, 2025 (USD Million)
Europe Biosimilars Market, By Country, 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

U.S. dominated the North America biosimilars market, accounting for around USD 655.6  million in the year 2018. The U.S. captured the majority market share of the North America market owing to presence of primary new technology and state-of-art facilities for biosimilar production. Also, recent biosimilar approvals by FDA in the year 2015 will result in rapid biosimilar adoption, augmenting the market growth. During the forecast years, it will witness significant growth owing to relatively low addressable needs.
 

India market will observe rapid growth rate of 26.7% over the forecast period. The growth is credited to rising prevalence of chronic diseases due to growing lifestyle-related habits and increase in trends of tobacco intake in millennials. Furthermore, expansion of new healthcare facilities, development of hospitals, and growing acceptance of private clinics have boosted the industry growth. Also, increase in R&D activities in the country by major player such as Biocon, Zydus Cadila etc. will boost the sales of biosimilars.
 

Competitive Market Share

Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences are some of the major industry participants operating in the global biosimilars market. These key market participants are estimated to hold significant market share owing to better R&D capabilities, strong financial position, finest quality products and strong product pipeline. These players implement several strategies in order to gain competitive advantage over its competitors. Key strategies implemented by companies in the market include novel product launches, acquisition strategy, expansion strategy, etc.
 

Biosimilars Industry Background

Biosimilars market is estimated to grow at a substantial rate over the estimation period owing to patent expiration of well-known and bestselling biologic drugs. Biosimilars have become common in hospitals and clinics in the developed regions of Europe. The first biosimilar was approved in Europe in the year 2006 and since then over 40 biosimilars have been approved. The Europe market is estimated to show mature growth and follow similar trend whereas recent FDA approvals in the year 2015 will lead to rapid growth of biosimilars market in the United States. In the year 2017, several biosimilars were approved across the globe and since then there has been a rapid acceleration of biosimilars demand and adoption rate thereby, fueling the business growth. Big pharmaceutical companies have made considerable investments in development of further biosimilars, and many marketing authorization applications, particularly of monoclonal antibodies, are awaiting consideration by the several regulatory authorities. Hence, recent product approvals, low cost of the biosimilar drugs, reduction in the healthcare cost, patent expiration of the major biologics and growing R&D activities of the major pharma players will lead to drive the global market growth.
 


Buy Now

Single User: $5,150 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $7,150 Access for 2 to 5 users only within same department of one company
Enterprise User: $9,150 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Why Global Market Insights, Inc.?

Reliability & accuracy

  • GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.

Quality & trust


  • BBB Rating - Click to Verify

Customer service

  • Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.

Security & compliance

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X